Podcasts about Sabr

After the Phillies' 1-0 win over the Mets in Philadelphia on Monday night, is the National League East race now over? On Episode 1009 of Hittin' Season, John Stolnis of The Good Phight, Baseball Prospectus' Justin Klugh and Liz Roscher, Editor of SABR's Baseball Research Journal, discuss Aaron Nola's performance and the Phils' 8-game lead in the division with three more to play. Also, a discussion about Trea Turner's hamstring injury, Alec Bohm hitting the Injured List, and a conversation about America's newest villain, Philly Karen.

Dr. Beckett discusses his early collecting experiences, the culture and trends of card collecting from the 1950s through the 1960s, and key moments that shaped the hobby. Interviewed by Mark Armour and Jason Schwartz from SABR, Dr. Beckett shares personal anecdotes, the impact of moving frequently as a child, and how collecting methods varied across different neighborhoods and eras. He highlights iconic cards and sets, including the significance of the 1957 Topps set, the emergence of the Stan Musial All-Star card in 1958, and his cherished Christmas gift in 1959 that deepened his apssion for collecting.    01:31 Childhood Memories and Collecting Stories 03:21 Trading and Collecting Practices 05:08 Card Series and Releases 09:29 Evolution of Card Collecting 17:54 Christmas of 1959 and Family Influence  

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Against the team with the best record in baseball, the Phillies won two out of three this week and are in prime position for the No. 2 seed in the National League. On the latest Hittin' Season, John Stolnis of The Good Phight and Liz Roscher, editor of SABR's Baseball Research Journal, recap a fun series in Milwaukee, discuss Aaron Nola's future, Harrison Bader's surge, the outfield platoon and preview this upcoming weekend in the National League. Chapters: 00:00 - Injury Updates and Series Overview 03:03 - Phillies vs. Brewers: A Playoff Preview? 06:05 - Key Performances and Clutch Moments 08:53 - Outfield Dynamics and Player Changes 11:56 - Ranger Suarez: The Emerging No. 2 14:45 - Aaron Nola's Performance and Future Outlook 30:33 - Phillies' Pitching Dilemmas and Playoff Considerations 35:37 - Kyle Schwarber's Slump and Offensive Impact 39:01 - Upcoming Series vs. Marlins and NL Weekend Slate

"Feel and timing” is a mysterious concept for many riders because no one ever explains what it actually is, or how to grow it. In this episode, Jake breaks it down into what he calls the "four-factor awareness model" — Softness, Acceptance, Balance, Rhythm (SABR). These four layers act like tumblers on a combination lock: at first you just reward basic physical compliance, then mental relaxation, then true balance, and finally rhythm as the capstone. SABR gives you a roadmap, both for teaching any maneuver and refining your own feel in the saddle. If you've ever wondered how expert trainers seem to “just know,” this episode decodes the structure behind that awareness.

On Labor Day, the Phillies won a thriller over the Brewers for what was easily their best win of the season. On Episode 1007 of Hittin' Season, John Stolnis of The Good Phight, Liz Roscher, Editor of SABR's Baseball Research Journal, and Justin Klugh of Baseball Prospectus discuss Monday's dramatic win, the impact of players like Garrett Stubbs and Harrison Bader, and the performance of the bullpen. As September approaches, the hosts make predictions about the team's chances in the playoffs and the potential for Kyle Schwarber to break Ryan Howard's home run record. Chapters: 00:00 - Phillies' Dramatic Win Over the Brewers 02:59 - Justin Klugh's Upcoming Book on the 1941 Phillies 05:49 - Resilience in the Face of Adversity 09:04 - Key Players Making a Difference 11:53 - The Impact of Garrett Stubbs' Return 14:53 - Harrison Bader's Contributions to the Team 18:02 - Future Considerations for the Phillies 20:55 - Did Realmuto Swing? 26:08 - Managing Player Dynamics: Rob Thompson's Approach 34:38 - Analyzing the Brewers: Strengths and Weaknesses 39:38 - Phillies' Resilience: Learning from Past Series 42:11 - Bullpen Concerns: Navigating Late-Season Challenges 52:38 - September Predictions: Home Run Records and Team Performance 54:22 - Home Run Records and Player Performance 56:20 - Pitching Prospects: Ranger Suarez vs. Jesus Luzardo 59:20 - Aaron Nola's Final Month and Team Dynamics 01:01:11 - Phillies' Division Chances and Playoff Prospects 01:07:15 - Final Thoughts and Reflections on the Season

Apologies for an extra re-run this month. Mike is dealing with a personal thing, and we will be back with a new episode next week. Some people podcast about history. Some people witness it. Melissa Ludtke made it happen, successfully fighting back against Bowie Kuhn and Major League Baseball to ensure women in journalism could be on equal footing with male sportswriters. Mike, Bill and Mike Duncan (@MikeDuncan) talk with her about that experience, about the importance of representation for women in baseball, and about the book she was working on at the time. This book is now finished and is called Locker Room Talk: A Woman's Struggle To Get Inside. It's fantastic.

Dr. Beckett recaps episodes 1401 through 1424, expressing gratitude to loyal listeners for their active participation. The episode covers various topics, such as tributes to sports dignitaries like Dave Parker, discussions on the feasibility of a sports card cruise with AI involvement, and an insightful exchange with Iowa Dave Schwartz. The episode also includes special presentations from the SABR convention, conversations on rookie cards, and reflections on the 2025 Chicago National. Additionally, Dr. Beckett delves into Panini's blockchain initiatives and Upper Deck's unique approach to hockey cards, among other subjects.    00:34 Tributes to Sports Legends 01:14 AI and Sports Card Cruise 01:40 Dueling Questions and SABR Presentation 03:37 National Perspectives and Pre-National Ramblings 06:41 Panini Blockchain and Upper Deck Innovations 08:21 Sports Card History and T206 Set    

Round one goes to the Mets, clobbering the Phillies in Monday's opener of a crucial three-game series between the two clubs vying for first in the National League East. On Episode 1003 of Hittin' Season, John Stolnis of The Good Phight, Justin Klugh from Baseball Prospectus and SABR's Liz Roscher chat about a brutal night at Citi Field, the Phils' own personal House of Horrors over the last three seasons. The offense blew scoring chances early, Cristopher Sanchez couldn't hold a lead, the defense was brutal, and yes, Jordan Romano entered the festivities. What does it mean for the rest of the week? How vital is at least one win from the Mets by Wednesday? Chapters 00:00 - Introduction and Initial Reactions 02:43 - Game Overview and Key Moments 05:42 - Phillies' Performance and Missed Opportunities 08:44 - Historical Struggles at Citi Field 11:30 - Emotional Impact of Rivalry Games 14:41 - Pitching Decisions and Game Management 17:40 - Conclusion and Future Outlook 24:52 - Game Analysis and Player Performance 27:36 - Struggles Against Rival Bullpens 30:09 - Frustrations of Phillies Fans 35:18 - Bryce Harper's Rivalry Pack 43:11 - Karma and Performance Metrics 46:27 - The Impact of Zach Wheeler's Injury 48:45 - Rallying for Wheeler 52:05 - The Depth of the Phillies' Rotation 55:24 - Final Thoughts on the Season

In this episode of 'Conversations in Lung Cancer Research,' A/Prof Mel Moore sits down with A/Prof Fiona Hegi Johnson, a radiation oncologist at the Peter McCallum Cancer Center and senior research fellow at the University of Melbourne. Fiona shares her journey into radiation oncology, highlighting her career progression, the impact of serendipity, and the importance of mentors. They discuss technological advancements in the field, the role of multidisciplinary teams, changes in lung cancer treatments, and clinical challenges. Fiona offers insights into balancing clinical work with research and provides advice for early-career professionals in the field.(00:00) Introduction and Acknowledgements(00:32) Guest Introduction: Associate Professor Fiona Hegi Johnson(01:33) Fiona's Career Journey and Early Challenges(04:08) Choosing Radiation Oncology(06:04) Balancing Clinical and Academic Roles(09:46) Challenges in Radiation Oncology Research(13:45) Technological Advances in Lung Cancer Treatment(17:22) Multidisciplinary Team Dynamics(23:03) Fiona's Role in TROG and Mentorship(28:32) Advice for Early Career Professionals(30:02) Conclusion and Final Thoughts

After another late inning win over the Reds Monday night, the Phillies roll continues with contributions up and down the lineup and from the most pleasant surprise of the season - Taijuan Walker. On Episode 997 of Hittin' Season, John Stolnis of The Good Phight and Liz Roscher of SABR's Baseball Research Journal discuss the weekend sweep of the Rangers, the remarkable turnaround of the Jhoan Duran-led bullpen, Zack Wheeler's velocity drop and the freefalling Mets.

On Episode 994 of Hittin' Season, powered by WHYY, John Stolnis of SB Nation's The Good Phight, Justin Klugh from Baseball Prospectus and SABR's Liz Roscher discuss the Phillies' series win over Detroit and their Monday night 13-3 blowout of the Baltimore Orioles, highlighting key players like Kyle Schwarber and Christopher Sanchez. They delve into the MVP candidacy of Schwarber, compare his stats with Shohei Ohtani, and analyze the outfield situation, particularly the struggles of Max Kepler. The conversation also touches on Zack Wheeler's recent performance and injury updates for the Phils. Chapters 00:00 - Introduction and Game Overview 02:46 - Phillies' Performance and Player Highlights 05:27 - Kyle Schwarber's MVP Candidacy 08:37 - Comparing Stats: Schwarber vs. Ohtani 11:34 - Contract Talks and Future Considerations 14:30 - Outfield Dynamics and Player Decisions 21:09 - Max Kepler's Struggles and Stats 23:31 - Outfield Decisions and Roster Moves 25:56 - Power Surge: Phillies' Offense in the Second Half 29:29 - The Importance of Comeback Wins 33:42 - The Jhoan Duran Effect: A New Closer's Impact 39:26 - Christopher Sanchez: Rising Star in the Rotation 47:13 - Concerns About Zach Wheeler 54:28 - Injury Updates and Final Thoughts

En el mundo existen más de 250 razas de gatos: calvos y peludos, gruñones y amistosos, cariñosos e independientes. ¿Cuánto cuesta la raza más cara? ¿Sabrías decirlo? Para ser sinceros, estarás sorprendido al descubrir los precios de los gatos más exóticos del mundo. ¿Sabes cuál es el más caro? Este gato es muy costoso pero increíblemente hermoso. Learn more about your ad choices. Visit megaphone.fm/adchoices

Bo Carter is the Executive Director for the National Collegiate Baseball Writers Association and an inductee into the College Sports Communicators Hall of Fame. He was media relations director for the Southwest Conference (SWC) and Big 12 Conference for a combined 22 years. His essay, "Southwest Conference Baseball HIstory," was appears in The National Pastime: Baseball in Texas and Beyond (Society of American Baseball Research (SABR), 2005). Carter has been a SABR member since 1993. Bo Carter on SABR - https://sabr.org/authors/bo-carter/"Southwest Conference Baseball History" - https://sabr.org/journal/article/southwest-conference-baseball-history/National Collegiate Baseball Writers Association - https://www.sportswriters.net/ncbwa/Errata: On further review, Southwestern's Curt Walker was not the first former SWC player to reach the majors, though he was the first to enjoy a substantial MLB career. Maybe that's for another episode? Hooks & Runs - https://hooksandruns.buzzsprout.comEmail: hooksandruns@protonmail.comCraig on Bluesky (@craigest.bsky.social)Rex (Krazy Karl's Music Emporium) on Facebookhttps://www.facebook.com/people/Krazy-Karlz-Music-Emporium/100063801500293/Hosts Emeriti:Andrew Eckhoff on TikTokhttps://www.tiktok.com/@hofffestEric on Facebookhttps://www.facebook.com/ichaboderic/Music: "Warrior of Light" by ikolics (via Premium Beat)   www.premiumbeat.com/artist/ikoliksThis podcast and this episode are copyright Craig Estlinbaum, 2025.   

Pero que mejor broche de temporada que la visita en el estudio de Iñaki Kerejazu... CELEDÓN!!!!

En este episodio de expresiones queremos hablar de cinco expresiones que contienen la palabra “codo”. Sabrás por qué es positivo “hincar los codos” y por qué suele ser negativo “empinar el codo”. Muchas gracias por escucharnos, si quieres acceder a ventajas y apoyar este podcast hazte suscriptor premium en: www.hoyhablamos.com Editar extracto

On Episode 991 of Hittin' Season, powered by WHYY, the Good Phight's John Stolnis, Justin Klugh of Baseball Prospectus and editor of SABR's Baseball Research Journal Liz Roscher offer their predictions on what Dave Dombrowski will do at the Trade Deadline this Thursday. Relievers? Bats? Both? Neither? Also, Bryce Harper goes nose-to-nose with Rob Manfred in a heated clubhouse meeting over a potential salary cap, and we recap a mostly good series in the Bronx and a bad start to their series in Chicago Monday night. Takeaways The Phillies are struggling to maintain consistent performance, especially against weaker teams. JT Real Muto's resurgence has significantly improved the Phillies' lineup. The trade deadline is approaching, and the Phillies need to prioritize bullpen help. Bryce Harper's vocal stance against a salary cap highlights player concerns about management's intentions. The dynamics between players and management are tense, especially with Rob Manfred's recent actions. The potential trade market is thinning, making it harder for the Phillies to acquire top talent. Players are increasingly aware of the economic challenges facing baseball and are willing to fight for their rights. The role of former players in management can complicate relationships with current players. The Phillies' management must balance short-term needs with long-term player development. The upcoming trade deadline could significantly impact the team's playoff chances. Chapters 00:00 - Introduction and Overview of the Phillies' Current Situation 04:47 - Trade Deadline Insights and Player Performance 09:49 - The Impact of Key Players on the Phillies' Lineup 14:53 - Analyzing the Phillies' Trade Needs and Strategies 19:47 - Recent Trade Rumors and Market Dynamics 24:48 - Injury Updates and Their Implications for Trades 29:30 - Final Thoughts on the Trade Deadline and Team Prospects 36:17 - Bryce Harper vs. Rob Manfred: Tensions Rise 42:29 - The Impact of Former Players on Current Negotiations Keywords Phillies, trade deadline, Rob Manfred, Bryce Harper, JT Real Muto, MLB, baseball, player performance, labor issues, team dynamics

Nuria Richart repasa canciones que fueron éxitos pero que actualmente estarían vetadas. No es un buen verano para Pedro Sánchez. No sólo le costará salir al paseo marítimo a tomarse un helado, desde hace meses los ciudadanos le esperan con una buena dosis de abucheos, si no que una de sus aficiones más conocidas, la música en directo, ha pasado a ser de riesgo. Nada más llegar al gobierno fue muy sonado el uso privado que hizo del Falcon para irse al FIB, el Festival Internacional de Benicasim. En aquella ocasión Moncloa dijo que era "por interés general del país". El 4 de julio en Llanera (Asturias) Víctor de Andrés, el guitarra del grupo de folk-metal Mägo de Oz, en un momento del concierto cogió el micrófono y dijo: "¡Pedro Sánchez, hijo de puta!", "¡Sánchez, me cago en tus muertos, gilipollas!". Y añadía, en alusión a la trama de Koldo, Ábalos y Cerdán: "Os voy a decir una cosa para que esto no se repita jamás en la historia: me da igual que gobierne quien gobierne, dejad de robarnos sobre todo la cocaína y las putas". El público le siguió con cánticos contra el Presidente del Gobierno. No es la primera vez que en un concierto o evento el público se corea algo parecido. Ocurrió lo mismo, por ejemplo, en la actuación que el dj Juan Magán ofreció en Arganda del Rey hace pocas semanas. Interrumpió el espectáculo y con una sonrisa dijo: "Es que yo no puedo decir estas cosas, pero…", y extendió el micro a los asistentes.El PSOE cancela a Mägo de Oz en Villagarcía de Arosa por meterse con Pedro Sánchez en otro conciertoNuria Richart Pues la primera reacción del PSOE se ha producido en la localidad pontevedresa de Villagarcía de Arosa, donde se ha cancelado la actuación que Mägo tenía previsto ofrecer el 19 de agosto en las fiestas locales de San Roque. El ayuntamiento, gobernado por el socialista Alberto Varela, ha argumentado que lo que hicieron en Llanera son "frivolizaciones" sobre las drogas y la prostitución. Parece que les escandaliza más lo que se opina desde un escenario que lo que hacen sus propios compañeros de partido. Podemos Galicia, que no tiene representación municipal, apoyó al PSOE diciendo que: "frases como "deixade de roubarnos a cocaína e as putas" non son só de mal gusto: son machistas, groseiras e violentas". En su lugar actuarán Los Toreros Muertos, banda liderada por Pablo Carbonell. ¿Sabrá el PSOE que este grupo tiene un tema que se llama "Falangista"?Canciones de putas, palizas y homosexuales Hubo días en España en los que nos escandalizábamos menos y bailábamos una banda sonora que bien podríamos dedicar hoy a Ábalos, a los fiesteros socialistas de los paradores a los que no oyó Pilar Alegría o a la familia Sánchez-Gómez y sus negocios de saunas gais. En la sección No te Equiwokes de La Trinchera de Llamas hemos seleccionado sólo algunos ejemplos de temas sobre pingos verbeneros, homosexuales y agresiones sin censura, para provocar a los neoconservadores progres: Loquillo y su "Himno de prostitutas" (1985). "Cuanta puta y yo qué viejo" de Siniestro Total. Una letra sin complejos: "Papaíto entra. ¿qué me haces rockero? / Las niñas bonitas cobran mucho más dinero / Mujeres desnudas con hombres desnudos / ¿Qué es lo que hacen cuando están todos juntos? / Cuánta puta y yo qué viejo". "Me gusta ser una zorra" de Vulpes. En el año 1983 la interpretaron en el programa de TVE Caja de ritmos, dirigido por Carlos Tena, que se emitía en horario infantil. El Fiscal general del Estado, Luis Burón, presentó una querella por escándalo público y al final Tena dimitió. La magnífica "Miss Carrusel" de Nacho Vegas (2001) de su disco "Actos Inexplicables". "Una canción para la Magdalena" de Joaquín Sabina (1999). "Geishas en Madrid" de Ariel Rot (2000). "Me llaman calle" de Manu Chao (2007). "Buena chica" de Los secretos. (1991). Canción dedicada a Luisa Martínez, drogadicta y amiga personal de Enrique Urquijo. La archiconocida "Roxane" de The Police (1978). Un hombre se enamora de una prostituta y le pide que abandone esa vida. En la sección hemos aprovechado para recomendar otras canciones para desintoxicarse del wokismo: "La ramona pechugona" de Fernando Esteso. Canción del año 1976. En tiempos de delitos de odio por gordofobia escuchar esto de: "La Ramona es barrigona su cuerpo da miedo verlo / La Ramona es pechugona tié dos cantaros por pechos / Los brazos de la Ramona son mas anchos que mi cuerpo / Le han hecho un retrato en casa del retratero, como era tan gorda solo ha salío medio cuerpo", es bastante fuerte. "Sí, sí" de Los Ronaldos. En el año 1987 Coque Malla cantaba: "Estas haciendo mal al dejarme pasar / estas haciendo mal y no se lo que va a pasar. / Tendría que besarte, desnudarte, "pegarte" y luego "violarte" / hasta que digas sí. / Mírame el ojo derecho niña y dime que ves en el / seguro que hay ansia y fuego muchas pagarían por el". "La mataré" de Loquillo y los Trogloditas. "La cintura morena que me volvió loco / llevo un velo de sangre en la mirada / y un deseo en el alma / que jamás la encuentre / Sólo quiero que una vez/ algo la haga conmover / Que no la encuentre jamás / o sé que la mataré / Por favor sólo quiero matarla / A punta de navaja/ Besándola una vez más". "Uma Thurman me toca la banana" de los Petersellers. Escena de placer en soledad: "Me paso las horas tratando de encontrar / una mano amiga que me ayuda a caminar / el mando está caliente y mi mano se resiente / el volumen bajo mientras oigo a Supertramp / Uma Thurman me toca la banana, ¡hey! Uma Thurman me toca la banana". Siniestro Total tiene muchas antiwoke, sin que existiera todavía esta palabra: "Más vale ser punkie que maricón de playa", "Ayatollah!" (no me toques la pirola) o "¿Qué tal homosexual?". ¿Cuántos padres siguen poniendo a sus hijos "Así planchaba" de los Payasos de la Tele? En YouTube es más fácil encontrar la que se ha hecho ahora con la versión en masculino. Mägo de Oz ha tenido que sacar un comunicado en el que dice: "No aceptamos chantajes ni lecciones de moralidad". Nada más que añadir.

Episode 301 features Donna Muscarella, President of the Elysian Fields SABR Chapter and Steven Chase, founder of Steve's Original Sauces      Donna Muscarella is a baseball enthusiast, photographer, and mixed-media artist.  Hinchliffe Stadium, one of the few Negro Leagues ballparks still standing, is a repeat subject of Donna's creative compositions.  In 2021, she released her debut trading card set, which used her photography of the historic ballpark on the card fronts.  The card backs featured information about Hinchliffe's Negro Leagues ties.  Donna's Hinchliffe photography appeared on Forbes.com, in the third edition of Turnstyle:  The SABR Journal of Baseball Arts, and her card set was featured on the SABR Baseball Cards Blog.  She has covered events at Hinchliffe Stadium for the National Baseball Hall of Fame and the Charles J. Muth Museum of Hinchliffe Stadium.  Donna serves as president of the Elysian Fields (Northern New Jersey) Chapter of the Society for American Baseball Research (SABR).  Go to  https://linktr.ee/TheLensOfDonnaM  to see more of Donna's artwork.    Stephen Chase is the chef and founder of Steve's Original Sauces, otherwise known as SOS.  Stated on their website, "At Steve's Original Sauces, we believe that every culinary creation deserves a touch of artistry, a dash of passion, and an infusion of exquisite flavor. Founded in the quaint town of Belmont in 2018 by the visionary Stephen Chase, our journey began with a singular mission: to elevate the everyday dining experience through a curated selection of gourmet sauces and syrups that tantalize the palate and inspire the imagination.  As we continue to grow, we remain steadfast in our dedication to creating products that resonate with the discerning tastes of our clientele."  For more information or to make a purchase go to  https://stevesoriginalsauces.com/    We recommend you go to Baseball BBQ, https://baseballbbq.com for special grilling tools and accessories, Magnechef https://magnechef.com/ for excellent and unique barbecue gloves, Cutting Edge Firewood High Quality Kiln Dried Firewood - Cutting Edge Firewood in Atlanta for high quality firewood and cooking wood, Mantis BBQ, https://mantisbbq.com/ to purchase their outstanding sauces with a portion of the proceeds being donated to the Kidney Project, and for exceptional sauces, Elda's Kitchen https://eldaskitchen.com/   We conclude the show with the song, Baseball Always Brings You Home from the musician, Dave Dresser and the poet, Shel Krakofsky. We truly appreciate our listeners and hope that all of you are staying safe. If you would like to contact the show, we would love to hear from you. Call the show:  (516) 855-8214 Email:  baseballandbbq@gmail.com Twitter:  @baseballandbbq Instagram:  baseballandbarbecue YouTube:  baseball and bbq Website:  https//baseballandbbq.weebly.com Facebook:  baseball and bbq

For so long, we've thought that the 4,000 hit club was one of the most exclusive in baseball history, with just two members. But on the 98th anniversary of Ty Cobb's 4,000th hit, Mike and Bill are joined by Sports Reference's Executive Director of Design, Negro Leagues expert and Latin baseball researcher Adam Darowski (@adarowski.bsky.social) to talk about his presentation at SABR 53, and how much larger that club actually is. The answer, and the players on it, will surprise you and hopefully expand your horizons about what should count toward the record book of baseball. Plus, happy birthday to Rubén Gómez and to Jesse Tannehill! And farewell to Mark Esser, Jack Curtis, Rod Nichols, and Jason Conti. Here's the link to the SABR 53 presentations, where you can find audio and slides from Adam's talk: https://sabr.org/convention/sabr53-presentations

¿Sabías que, en 1907, un médico midió 21 g al “peso del alma” justo en el instante de la muerte? ⚖️ Hoy no vamos a pesar almas, pero sí vamos a cartografiar la depresión: un vacío que, cuanto más hueco se vuelve, más pesa en nuestro día a día. En este episodio viajamos desde la leyenda de esos 21 gramos hasta la ciencia puntera de 2024, cuando la Universidad de Stanford identificó 6 biotipos cerebrales distintos de depresión y demostró que no todos los cerebros se deprimen igual. A lo largo de una hora de conversación combinamos historia, neurociencia y testimonios reales para iluminar: Qué es y qué NO es la depresión (spoiler: no es simple tristeza ni “falta de ganas”). Los factores biológicos, sociales y contextuales que la desencadenan y mantienen. El hallazgo de los marcadores cerebrales: desde la sobrecarga de la red por defecto (rumiación sin freno) hasta la “parálisis por análisis” de la corteza prefrontal. El biotipo “Insome” y cómo el insomnio desajusta tu reloj interno. El biotipo de la “Ola emocional”, donde la amígdala arde y cada estímulo se siente a 100 000 V. Estrategias prácticas: rTMS, ACT, DBT, cronoterapia, mindfulness… y cómo elegir la adecuada para TU biotipo. Te contaremos por qué Finlandia puede encabezar el ranking de países más felices y, aun así, luchar contra una tasa de suicidio elevada , y qué nos enseña eso sobre la diferencia entre “vida satisfactoria” y “bienestar emocional”. Al terminar el episodio: Sabrás describir tu propia experiencia con palabras precisas (¡o al menos sentirás que ya no estás solo!). Tendrás un mapa con las rutas terapéuticas mejor adaptadas a cada tipo de depresión. Contarás con una playlist de prácticas sencillas para activar tu ánimo incluso cuando la niebla sea densa. Recursos y comunidad (¡haz clic y acompáñanos!) Nuestro nuevo libro Nuestra escuela de ansiedad Visita nuestra web Facebook Instagram ▶️ YouTube AMADAG TV Palabras clave depresión,biotipos,Stanford,neurociencia,salud mental,21 gramos,Duncan MacDougall,DSM5,anhedonia,rutinas de sueño,rumiación,amígdala,corteza prefrontal,red por defecto,insomnio,terapia cognitiva,técnicas de mindfulness,ACT,TMS,antidepresivos,análisis neuroimagen,marcadores biológicos,La teoría de la mente,podcast psicología,AMADAG Hashtags #Depresión,#SaludMental,#Neurociencia,#LaTeoríaDeLaMente,#PodcastPsicología,#AMADAG 5 títulos atractivos para tu plataforma de podcasts 4 hábitos que te ayudarán a que la depresión pierda peso (¡y no son “pensar en positivo”!) ✨ Deja de luchar contra la tristeza así… y descubre por qué no funciona ⚠️ Esta forma de mirar tu cerebro cambiará para siempre el tratamiento de la depresión 5 cosas que nunca te contaron sobre la depresión… y que tu bienestar necesita saber ¿Y si tu tristeza fuera de otro “tipo”? Descubre el biotipo que está frenando tu ánimo ️ Pon los auriculares, pulsa play y acompáñanos en la investigación más humana de todas: la del alma que busca recuperar su luz.

Salmo 23:1-3

Dr. Beckett and Rich Klein dive into the intersections of baseball cards, baseball history, and sabermetrics. The episode covers valuable topics such as the evolution of card photography, the rarity and value of checklist cards, the differences in grading standards among major companies, and strategies for valuing personal collections. They also share anecdotes about the card industry and discuss how the COVID-19 pandemic and new market players have influenced the hobby's growth.   00:49 Challenges of the Card Market in the 80s 02:08 The Process Behind Baseball Card Photography 04:00 The Rarity and Value of Checklist Cards 04:38 Card Grading Standards and Market Perception 08:27 Advice for Valuing and Selling Your Collection 09:26 Impact of COVID-19 on Sports Card Collecting 11:05 Trend of One-of-One Cards 12:05 Interactions with Card Companies 13:22 Renata Galasso and Her Impact on the Hobby  

On Episode 985 of Hittin' Season, powered by WHYY, John Stolnis of The Good Phight, Justin Klugh from Baseball Prospectus and Liz Roscher, Editor of SABR's Baseball Research Journal, review the first half of the Phillies' 2025 season and wonder, how are the Phillies in first place? Also, John, Justin and Liz dive into a trivia challenge centered around the Philadelphia Phillies and their All-Star Game history, flowing through various milestones, memorable moments, and anecdotes from past All-Star Game. 00:00 Introduction and Overview of the Phillies' Season 02:40 Home Run Derby Highlights and Player Performances 05:28 Phillies' First Half Performance and Team Dynamics 08:42 Strengths and Weaknesses of the Phillies' Roster 11:37 Reflections on the First Half and Comparisons to Other Teams 14:46 Grading the Players: Starting Pitching and Offense 17:37 Bryce Harper's Impact and Expectations 20:33 Assessing the Bullpen and Overall Team Performance 23:30 Final Thoughts and All-Star Trivia 40:11 Trade Deadline Predictions 42:39 All-Star Game Trivia Fun 53:38 Milestones and Memorable Moments 59:16 All-Star Game Trivia Begins 01:02:18 Milestones and Historical Context 01:05:07 The Evolution of the Vet Stadium 01:07:43 Home Run Derby Highlights 01:11:31 Memorable All-Star Moments 01:15:17 Final Trivia Challenge and Wrap-Up

Dr. Beckett shares his remarks from the recent SABR Annual Convention #53. Along with Rich Klein and moderated by Paul Rogers, they delve into the evolution of sports card collecting, the transition from hobby to business, and the shifting dynamics within the industry. They discuss the changes in card pricing, the rise of modern cards, and the ongoing passion that drives collectors.   01:21 Early Days and Personal Journey 05:30 Challenges and Transitions 10:46 Evolution of the Hobby 14:05 Modern vs. Vintage Cards    

You can find a transcript of the episode hereOn this episode, our Mark Simon talks to Astros rookie right fielder Cam Smith, who ranks among the leaders in Defensive Runs Saved despite never having played the position before this season.Cam talked about his welcome to the big leagues' moments and explained how teammate Jake Meyers and the Astros outfield coaches have helped in his acclimation to a new position.Then, we switched topics. Mark went to the SABR convention and shared some of the things he learned, and brought on Sports-Reference's executive director of design Adam Darowski to share his research about players with 4,000 hits in pro baseball.Lastly, Mark and his colleague Ben Schneider talked about what SIS measures regarding home plate umpire performance and looked at some tendencies among MLB umpires the last couple of seasons.Three good interviews/discussions in roughly 20 minutes!Thanks as always for listening. Please check out the new-and-improved FieldingBible.com website, follow us on Bluesky at @sportsinfosolutions.com, and read our work at SportsInfoSolutions.com. You can e-mail us at Mark@sportsinfosolutions.com.

Patrick joined Chrystal again to briefly discuss what's going on with the Guardians and help break down the series. Here is what they talked about: What's new with the Guardians A bad stretch and mounting frustrations Pitching has not been an issue Trade rumors Rating the offseason and trade deadline hopes Can the Guardians catch up to the Tigers, or are they destined to try for a Wild Card spot this season? Running out of room for improvement How Pat feels about the season All-Star picks What to expect from Guardians pitchers What the bullpen lacks Biggest threat to the White Sox Keys to winning the series Fears heading into the series Pitchers are starting to go longer The ASG in Atlanta You can find Patrick Ellington Jr. in many places! You can follow him on Bluesky and/or Twitter. I would also recommend reading his work on Substack. You can also read his work on Baseball Prospectus and SABR. Learn more about your ad choices. Visit megaphone.fm/adchoices

On Episode 982 of Hittin' Season, powered by WHYY, the Good Phight's John Stolnis, Justin Klugh of Baseball Prospectus and Liz Roscher from SABR's Baseball Research Journal discuss the historic pitching performance of Zack Wheeler and why the Phillies cannot waste his performance, and the starting rotation, by being passive at the trade deadline. Also, thoughts on All Stars Wheeler and Kyle Schwarber, snubs, and concerns over Bryce Harper's wrist continue.

Chapter on Patience (Sabr) - Lesson 6 by Albaseerah

With the boys still recovering from SABR last week in Dallas, it's a perfect time to revisit the great Larry Doby, who never gets nearly enough attention.  It's probably fair to say that no more important player in baseball history has been talked about less than Larry Doby, the second African-American to break the color line as a player and a manager, which happened 73 and 42 years ago this week, respectively. Mike and Bill try to rectify that just a little, looking back at Doby's life before getting the chance to integrate the American League and the incredible contributions he made after it. Plus, happy birthday to Al Downing and Tony Armas Sr! Back next week with a new episode.

La entrega número 845 de La Dosis el Podcast te ofrece los motivos para identificar si tu pareja posee una mentalidad limitada en cuanto al dinero. La ambientación sonora está en manos de Roral Ceef y la narración a cargo de Alejandro Andueza.La Dosis el Podcast es una producción de ETC CORP, tu consultora especializada en programas internacionales de intercambio que te permiten emigrar si tienes entre 18 y 56 años. Si te interesa conocer qué opciones laborales existen para ti en el extranjero, escribe la palabra PODCAST al WhatsApp disponible en este enlace: https://wa.me/13057218760. Allí recibirás una respuesta clara y directa sobre cuáles alternativas migratorias se ajustan a tu perfil, conforme a las normativas y convenios entre consulados y embajadas. Hosted on Acast. See acast.com/privacy for more information.

Mike and Bill are off this week at SABR and are getting this classic episode up late. In that spirit, please enjoy this encore presentation of Episode 298: With the White Sox threatening to leave the Windy City and abscond to Tampa if they didn't get a new stadium 37 years ago this week, and with the Illinois legislative session winding down to the end of its session and the funding bill a few votes short, he weirdest thing happened. Time, on (and only on) the floor of the state legislature, stopped for three whole minutes, giving the Governor and House Majority Leader time to rally the support necessary to pass the bill. In honor of this miracle, of sorts, Mike and Bill look back at the history of the original Comiskey Park, and the hijinks that ultimately led to its replacement. Plus, happy birthday to Alejandro Peña and Howie Pollett!

On Episode 976 of Hittin' Season, powered by WHYY, John Stolnis of The Good Phight, Justin Klugh from Baseball Prospectus and SABR's Editor of the Baseball Research Journal, Liz Roscher, recap the Phillies' emphatic series win over the Mets this weekend. Is this now officially a two-team race in the NL East? Did the Phils make a statement with their two blowout wins? Also, John, Justin and Liz talk about which Phillies are deserving of an All Star nod.

Actriz mexicana de cine, televisión y teatro, con notables participaciones en muchos de los títulos más destacados de la escena contemporánea. Entre sus trabajos más sobresalientes en teatro se encuentran ‘Todo Sobre mi Madre' (Dir. Francisco Franco), ‘Cock' (Dir. Toño Serrano), ‘Crímenes del Corazón' (Dir. Enrique Singer), ‘Medida por Medida' y ‘Medea' (Mauricio García Lozano), ‘Network' (Dir. Francisco Franco) con Daniel Giménez Cacho, y ‘Cabaret' (2024). Ha sido nominada al Premio Ariel en cinco ocasiones y a los Premios Platino en tres. Con ‘Las Niñas Bien' (Dir. Alejandra Márquez Abella) recibió el Premio Ariel en 2019 en la categoría de Mejor Actriz, además del premio del Festival Internacional de Cine de la Habana y el Festival Internacional de Lima. Con ‘Plaza Catedral' (Dir. Abner Benaim) recibió el reconocimiento del FICG como mejor interpretación. Ilse enlista más participaciones relevantes dentro de su filmografía, como ‘GÜEROS' ( Dir. Alonso Ruizpalacios), ‘Sabrás que Hacer Conmigo' (Dir. Katina Medina Mora), ‘Museo' (Dir. Alonso Ruizpalacios), ‘Cantinflas' (Dir. Sebastián del Amo), ‘Amores Modernos' (Dir. Matias Meyer), ‘Maquíllame Otra Vez' (Dir. Guillermo Calderón), ‘Familia' (Dir. Rodrigo García) y ‘Pedro Páramo' (Dir. Rodrigo Prieto). Para televisión, ha formado parte de proyectos como ‘Locas de Amor' (Televisa), ‘Capadocia' (HBO), ‘Sr. Ávila' (HBO), ‘Historia de un Crimen: Colosio' (Netflix), ‘100 Días para Enamorarnos' (Telemundo), ‘Señorita 89' (Fábula / Pantaya), ‘La Liberación' (Prime Video), serie de la que también es productora, y ‘Futuro Desierto' (Paramount Television), próxima a estrenarse.Síguenos en redes:http://instagram.com/cableatierrapodhttp://facebook.com/cableatierrapodcasthttp://instagram.com/tanialicious Hosted on Acast. See acast.com/privacy for more information.

Soy Guillermo Gascón y estás leyendo FailAgain, la newsletter sobre creación de contenido que se entrega los domingos en tu correo electrónico.En el contenido de hoy te cuento:* Por qué el email de bienvenida es el más importante (y el que casi todos descuidan)* Mi nuevo sistema al descubierto: los bloques importantes que lo construyen.* Un recurso que te puede ahorrar meses de dudas si quieres lanzar tu newsletter desde ceroPrepárate para optimizar la pieza clave de tu sistema.Hoy quiero hablarte del email más rentable y a la vez más olvidado de cualquier newsletter: el de bienvenida.Ese correo automático que se envía cuando alguien se suscribe.Al principio, yo tampoco le daba mucha importancia. Lo veía como un simple "gracias por suscribirte" y ciao. Un trámite. Pero con el tiempo, y después de ver las métricas, me di cuenta de una cosa que es demoledora:El email de bienvenida es el que tiene la tasa de apertura más alta. Y por goleada.No es raro que supere el 60% - 70%. Piénsalo: es el momento en el que la atención de tu nuevo suscriptor está al 100% contigo. Acaba de darte su correo y está esperando que le llegue algo.Pero su función va mucho más allá de causar una buena primera impresión. Es el primer elemento de una estrategia de éxito para tu newsletter.Cuando un suscriptor abre tu correo y, sobre todo, hace clic en algún enlace, le está enviando una señal potentísima a los servidores de Gmail y compañía. El mensaje es claro: "Oye, que esta persona y yo nos conocemos. Lo que me manda me interesa".Esa señal mejora tu reputación y aumenta las probabilidades de que tus futuros correos lleguen a la bandeja de entrada. Por eso, tu email de bienvenida no puede ser un simple trámite.De hecho, acabo de rediseñar el mío por completo para que sea el inicio de un sistema inteligente. Y te lo voy a desgranar aquí, pieza por pieza.Así funciona mi nuevo email de bienvenidaMi sistema ya no es un saludo y un enlace. Es una conversación estructurada en 5 bloques clave.Bloque 1: Conexión inmediataLo primero es que la persona piense: "Vale, este tío me entiende". Nada de rollos. Voy directo a su dolor: "construir un proyecto que nos apasione, y que crezca sin morir en el intento". Es un "no va a ser fácil, pero estoy contigo en esto".Bloque 2: El Regalo (con un pequeño giro)Acto seguido, entrego valor masivo (como diría Llados). Un taller práctico para crear un plan de contenido. Pero no es una descarga directa. Para acceder, pido contestar a 3 preguntas. ¿Por qué?* Provoco un clic: La interacción que le encanta a los gestores de correo.* Es un intercambio justo: Me das feedback sobre tus retos y, a cambio, no solo te llevas el taller, sino que me ayudas a que el contenido futuro esté más afinado a lo que de verdad necesitas. Ganas tú, gano yo.Bloque 3: Mi historia y mi porquéUna vez he entregado valor, me presento. Pero no con un currículum. Cuento mi historia, la de verdad: la de haberme quemado, la del síndrome del impostor... Cuento que FailAgain nació de esa frustración. Esto genera confianza. Dejo de ser un logo para ser una persona con una misión.Bloque 4: La promesaDespués de la historia, pongo las cartas sobre la mesa. Le digo exactamente qué va a recibir a partir de ahora: sistemas probados, procesos sin filtro y herramientas que suman. Gestiono sus expectativas para que sepa a qué atenerse. Cero sorpresas, cero humo.Bloque 5: Cierre y P.D. con trucoCierro de forma cercana y uso la posdata, que sé que todo el mundo lee, para las "tareas". Ahí le pido que mueva el correo a la bandeja principal y le recuerdo que acceda al taller. Es una forma de dar instrucciones sin que suene a orden militar.Vale, pero esto es solo el primer ladrillo...Tener un email de bienvenida potente es crucial. Es el cimiento. Pero una newsletter es un edificio entero.Si ahora mismo sientes que todo lo que rodea a crear una newsletter te abruma (la herramienta, la estrategia, el miedo a no saber qué escribir), quiero hablarte de algo que te va a abrir los ojos.Newsletter Fácil de Chus Naharro. Todo lo que tienes que aprender para poner en marcha una newsletter de forma seria, está en este curso.Tanto Chus como yo compartimos filosofía como creadores de contenido y su forma de trabajar (el "Método Farming"), es algo que no puedo dejar de recomendar: Sembrar, Cultivar y Cosechar. Se centra en construir una base sólida y una relación real con la audiencia, no en truquillos baratos.Esta formación es el camino más rápido para tener una newsletter con:* Claridad total: Sabrás exactamente cuál es tu temática, tu enfoque y ese valor diferencial que te hace único. Adiós al síndrome del impostor.* Un sistema anti-bloqueo: Chus te da un método sencillo para saber qué escribir en cada email y no volver a quedarte mirando la pantalla en blanco.* Confianza para vender: Aprenderás a integrar las ventas de forma natural y honesta, para que tu newsletter se convierta en un canal de ingresos sin sonar a teletienda.* Tu newsletter lista para enviar: Saldrás con todo configurado y preparado para lanzar en solo unos días, sin agobios ni líos técnicos.Si quieres dejar de dar vueltas y tener por fin un sistema paso a paso que funciona, la formación de Chus es el camino más directo que conozco.Mi objetivo con este email era enseñarte que el de bienvenida no es un correo más. Es una herramienta estratégica y si quieres hacer del email tu canal más importante te recomiendo que veas todo lo que tiene preparado Chus.Un saludo y a crear :)PD: Si rediseñas tu email siguiendo esto, mándamelo. Me encanta ver cómo aplicas estos sistemas y siempre puedo darte feedback específico.PD2: si quieres ver mi email de bienvenida completo y todos los bloques de información que contiene analizados, lo tienes en la comunidad Factoría Creativa This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.guitermo.com/subscribe

On Episode 973 of Hittin' Season, powered by WHYY in Philadelphia, The Good Phight's John Stolnis, Justin Klugh of Baseball Prospectus and Liz Roscher from SABR's Baseball Research Journal react to the Phillies' sudden winning streak after Monday's 5-2 win over the Marlins. Pitching heroes, bats that are now hot and Orion Kerkering the new closer? Plus, a spirited debate over AI in baseball and the Rafael Devers trade!

Chapter on Patience (Sabr) - Lesson 5 by Albaseerah

En este episodio de expresiones hablamos de varias frases que contienen la palabra gracia. Sabrás por qué a las personas que ganan la lotería las llamamos agraciadas o por qué algo que tenga gracia no va a ser necesariamente positivo. Muchas gracias por escucharnos, si quieres acceder a ventajas y apoyar este podcast hazte suscriptor premium en: www.hoyhablamos.com Editar extracto

Let's learn the rest of our conjugations of Saber, as well as a few new conjugations of Haber, including the subjunctive and the preterite. Practice all of today's Spanish for free at LCSPodcast.com/77  

On Episode 966 of Hittin' Season, John Stolnis of The Good Phight, Liz Roscher, Editor of SABR's Baseball Research Journal and Baseball Prospectus' Justin Klugh gather together to discuss the many high points of the Phillies' 6-1 road trip. How much does it matter the level of competition wasn't great? Also, they preview this week's series against the Braves in Philly. Is Atlanta any good?

The Philadelphia Phillies are currently atop of the NL East. However, we're asking the question on this podcast and during our interview: who are the Phillies? While they're having a successful season thus far, the Phillies have had ups and downs here in 2025. To dive into this question, the guys brought on friend of the pod Liz Roscher from the Hittin' Season podcast and the Society of American Baseball Research (SABR) for a great discussion to dissect what we've seen from the bats and arms this year. It was a great discussion!But first, the guys dove into some Philly sports history from this week. (Approx. 5:50)From there, the guys gave their thoughts on how the NFL owners decided not to ban The Tush Push, the famous play that has annoyed many NFL team. They also talked about how flag football will be coming to the 2028 Olympics. (Approx. 9:15)Then the guys discussed the NBA's Eastern and Western Conference Finals, the matchups and who they believe will head to the NBA Finals. Plus, might the Sixers be able to contend next year given their draft spot at No. 3 overall in the NBA Draft? Approx. 16:55)The guys then discussed how the Phillies are looking as they are first in the NL East. And yes, there are some fans who still are having issues with this team for some reason. (Approx. 40:55)What they threw down on the Table this week was a fantastic and in-depth discussion with Liz Roscher from the Hittin' Season podcast and SABR about the Phillies this season. The theme of the discussion was: who are the Phillies this season? What should we make of the bullpen and starting pitching here in May? Are the star veteran players doing what they need to do to help this team's identity? All of this and much more this week on the Table! (Approx. 48:15)SUBSCRIBE on YouTube: youtube.com/@thephiladelphiasportstableHead over to our website for all of our podcasts and more: philadelphiasportstable.comFollow us on BlueSky:Jeff: @jeffwarren.bsky.socialErik: @brickpollitt.bsky.socialFollow us on Threads:Jeff: @mrjeffwarrenErik: @slen1023The Show: @philadelphiasportstableFollow us on Twitter/X:Jeff: @Jeffrey_WarrenErik: @BrickPollittThe Show: @PhiladelphiaPSTFollow us on Instagram:Jeff: @mrjeffwarrenErik: @slen1023The Show: @philadelphiasportstableFollow Jeff on TikTok: @mrjeffwarrenFollow us on Facebook: facebook.com/PhiladelphiaSportsTable

Eds continues to deal as he finishes off the Christie Pits saga with the story of the 1933 riot that had been brewing on the streets of Toronto for years. The rise of anti-semitism in Hogtown and around the world catalyzed a six hour race riot between the Jewish youth of the city, their Italian neighbours and the Nazi punks that wished to see them banned from public spaces.  Special Thanks to Stephen Dame of SABR for anchoring most of the research for this story. Check out his article at sabr.org or the Fall 2023 editions of SABR's baseball research journal.

On Episode 963 of Hittin' Season, powered by WHYY in Philadelphia, John Stolnis from The Good Phight, SABR's Liz Roscher and Justin Klugh of Baseball Prospectus talk about Mick Abel's eye-opening MLB debut against the Pirates Sunday, and Jose Alvarado's shocking 80-game PED suspension that bars him from the 2025 postseason. Oh, and the Phils swept the Pirates, too.

Chapter on Patience (Sabr) - Lesson 4 by Albaseerah

Chapter on Patience (Sabr) - Lesson 3 by Albaseerah

Chapter on Patience (Sabr) - Lesson 2 by Albaseerah

On Episode 951 of Hittin' Season, John Stolnis of The Good Phight and SABR's Liz Roscher talk about Monday night's 5-4 loss to the Mets in New York, the Phillies' leaky bullpen, Aaron Nola now 0-5, Trea Turner and Bryce Harper's 9th inning ABs and more. Also, who's better right now, Jesus Luzardo or Cristopher Sanchez? And has Bryson Stott emerged as the answer in the leadoff spot? Plus, things aren't going so well in Atlanta for manager Brian Snitker.

Qalam Hangout: Sabr and Steadfastness - The Key to Victory (Juz 24 Reflections) 100% of your donations today goes towards the means of providing accessible Islamic knowledge to people around the world: supportqalam.com. Like us on Facebook: facebook.com/qalaminstitute Follow us on Twitter: twitter.com/qalaminstitute Follow us on Instagram: instagram.com/qalaminstitute Subscribe on Youtube: youtube.com/user/qalaminstitute